Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Infanrix hexa + Twinrix Junior
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Infanrix hexa + Twinrix Junior refers to a heterologous vaccination regimen evaluated by Laval University for the prevention of Hepatitis B in infants. Infanrix hexa is a hexavalent vaccine that provides protection against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b, and hepatitis B. Twinrix Junior is a bivalent vaccine designed to protect against both hepatitis A and hepatitis B. Both vaccines utilize recombinant hepatitis B surface antigen (HBsAg) as the active component for hepatitis B protection. The clinical focus of this combination, particularly in studies led by Laval University, is to compare the immunogenicity and efficacy of 2-dose versus 3-dose schedules in children aged 2 to 18 months, specifically monitoring the immune response to the hepatitis B component.
- Other names
- DTaP-IPV-Hib-HB + HAHBInfanrix-hexaTwinrix junior
02
Targets
HBsAg (Hepatitis B surface antigen)PV3 (Sabin) (Poliovirus type 3 antigen)PRNP (Cellular Prion Protein)Diphtheria toxinHepatitis A virus capsid protein
Beyond the preview
Go deeper on Infanrix hexa + Twinrix Junior.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Infanrix hexa + Twinrix Junior.